Literature DB >> 26842720

"It gives them more options": preferences for preconception genetic carrier screening for fragile X syndrome in primary healthcare.

Alison D Archibald1,2,3, Chriselle L Hickerton1, Samantha A Wake1,2,3, Alice M Jaques1, Jonathan Cohen4,5, Sylvia A Metcalfe6,7,8.   

Abstract

This study aims to explore stakeholder views about offering population-based genetic carrier screening for fragile X syndrome. A qualitative study using interviews and focus groups with stakeholders was undertaken to allow for an in-depth exploration of views and perceptions about practicalities of, and strategies for, offering carrier screening for fragile X syndrome to the general population in healthcare settings. A total of 188 stakeholders took part including healthcare providers (n = 81), relatives of people with fragile X syndrome (n = 29), and members of the general community (n = 78). The importance of raising community awareness about screening and providing appropriate support for carriers was emphasized. There was a preference for preconception carrier screening and for providing people with the opportunity to make an informed decision about screening. Primary care was highlighted as a setting which would ensure screening is accessible; however, challenges of offering screening in primary care were identified including time to discuss screening, knowledge about the test and possible outcomes, and the health professionals' approach to offering screening. With the increasing availability of genetic carrier tests, it is essential that research now focuses on evaluating approaches for the delivery of carrier screening programs. Primary healthcare is perceived as an appropriate setting through which to access the target population, and raising awareness is essential to making genetic screening more accessible to the general community.

Entities:  

Keywords:  Fragile X syndrome; Genetic counseling; Population carrier screening; Primary healthcare; Qualitative research

Year:  2016        PMID: 26842720      PMCID: PMC4796042          DOI: 10.1007/s12687-016-0262-8

Source DB:  PubMed          Journal:  J Community Genet        ISSN: 1868-310X


  41 in total

1.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

2.  "It's something I need to consider": decisions about carrier screening for fragile X syndrome in a population of non-pregnant women.

Authors:  Alison D Archibald; Alice M Jaques; Samantha Wake; Veronica R Collins; Jonathan Cohen; Sylvia A Metcalfe
Journal:  Am J Med Genet A       Date:  2009-12       Impact factor: 2.802

3.  A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study.

Authors:  Sylvia Metcalfe; Alice Jacques; Alison Archibald; Trent Burgess; Veronica Collins; Anna Henry; Kathleen McNamee; Leslie Sheffield; Howard Slater; Samantha Wake; Jonathan Cohen
Journal:  Genet Med       Date:  2008-07       Impact factor: 8.822

4.  Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization.

Authors:  E S Tambor; B A Bernhardt; G A Chase; R R Faden; G Geller; K J Hofman; N A Holtzman
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

5.  Fragile X population carrier screening.

Authors:  Sylvia A Metcalfe; Alison D Archibald; Genet Couns
Journal:  Genet Med       Date:  2012-03       Impact factor: 8.822

Review 6.  A systematic review of population screening for fragile X syndrome.

Authors:  Melissa K Hill; Alison D Archibald; Jonathan Cohen; Sylvia A Metcalfe
Journal:  Genet Med       Date:  2010-07       Impact factor: 8.822

7.  Fragile X syndrome: diagnostic and carrier testing.

Authors:  Stephanie Sherman; Beth A Pletcher; Deborah A Driscoll
Journal:  Genet Med       Date:  2005-10       Impact factor: 8.822

8.  Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research.

Authors:  Liane Ioannou; Belinda J McClaren; John Massie; Sharon Lewis; Sylvia A Metcalfe; Laura Forrest; Martin B Delatycki
Journal:  Genet Med       Date:  2013-09-12       Impact factor: 8.822

9.  ACMG position statement on prenatal/preconception expanded carrier screening.

Authors:  Wayne W Grody; Barry H Thompson; Anthony R Gregg; Lora H Bean; Kristin G Monaghan; Adele Schneider; Roger V Lebo
Journal:  Genet Med       Date:  2013-04-25       Impact factor: 8.822

10.  FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States.

Authors:  Flora Tassone; Ka Pou Iong; Tzu-Han Tong; Joyce Lo; Louise W Gane; Elizabeth Berry-Kravis; Danh Nguyen; Lisa Y Mu; Jennifer Laffin; Don B Bailey; Randi J Hagerman
Journal:  Genome Med       Date:  2012-12-21       Impact factor: 11.117

View more
  7 in total

1.  Informed decision making and psychosocial outcomes in pregnant and nonpregnant women offered population fragile X carrier screening.

Authors:  Sylvia A Metcalfe; Melissa Martyn; Alice Ames; Vicki Anderson; Alison D Archibald; Grad Dip Gen Couns; Rob Carter; Jonathan Cohen; Megan Cotter; M GenCouns; William Dang; Martin B Delatycki; Susan Donath; Samantha Edwards; PGrad Dip Educ; Grad Dip Gen Couns; Robin Forbes; Grad Dip Gen Couns; Mioara Gavrila; M MedSci; Jane Halliday; Chriselle Hickerton; Melissa Hill; Grad Dip Gen Couns; Lorilli Jacobs; PGrad Dip Ultrasound; Vicki Petrou; Grad Dip Gen Couns; Loren Plunkett; M GenCouns; Leslie Sheffield; F Racp; Alison Thornton; Grad Dip Gen Couns; Sandra Younie; PGrad Dip Hlth Econ; Jon D Emery
Journal:  Genet Med       Date:  2017-06-29       Impact factor: 8.822

2.  Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests.

Authors:  Alison Dalton Archibald; Melanie Jane Smith; Trent Burgess; Katrina Louise Scarff; Justine Elliott; Clare Elizabeth Hunt; Zoe McDonald; Caitlin Barns-Jenkins; Chelsea Holt; Karina Sandoval; Vanessa Siva Kumar; Lisa Ward; Emily Caroline Allen; Sarah Valerie Collis; Shannon Cowie; David Francis; Martin B Delatycki; Eppie Mildred Yiu; R John Massie; Mark Domenic Pertile; Desirée du Sart; Damien Bruno; David J Amor
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

3.  Health practitioners' perceptions of the barriers and enablers to the implementation of reproductive genetic carrier screening: A systematic review.

Authors:  Stephanie Best; Janet Long; Tahlia Theodorou; Sarah Hatem; Rebecca Lake; Alison Archibald; Lucinda Freeman; Jeffrey Braithwaite
Journal:  Prenat Diagn       Date:  2021-03-05       Impact factor: 3.050

4.  Fragile X premutation carrier screening in Pakistani preconception women in primary care consultation.

Authors:  Neelam Meraj; Muhammad Yasin; Zia Ur Rehman; Haleema Tahir; Humaira Jadoon; Niamat Khan; Rabia Shahid; Maria Zubair; Irba Zulfiqar; Musarrat Jabeen; Shahzadi Neelam; Abdul Hameed; Shamim Saleha
Journal:  BMC Womens Health       Date:  2022-03-04       Impact factor: 2.809

5.  Outcomes of Importance to Patients in Reproductive Genetic Carrier Screening: A Qualitative Study to Inform a Core Outcome Set.

Authors:  Ebony Richardson; Alison McEwen; Toby Newton-John; Ashley Crook; Chris Jacobs
Journal:  J Pers Med       Date:  2022-08-12

6.  Attitudes toward population screening among people living with fragile X syndrome in the UK: 'I wouldn't wish him away, I'd just wish his fragile X syndrome away'.

Authors:  Felicity K Boardman
Journal:  J Genet Couns       Date:  2020-11-12       Impact factor: 2.717

7.  Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR1 CGG repeat size.

Authors:  Emily Graves Allen; Krista Charen; Heather S Hipp; Lisa Shubeck; Ashima Amin; Weiya He; Sarah L Nolin; Anne Glicksman; Nicole Tortora; Bonnie McKinnon; Katharine E Shelly; Stephanie L Sherman
Journal:  Genet Med       Date:  2021-04-29       Impact factor: 8.822

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.